Time for change: conventional interferon regimes should not be the standard of care for management of pakistani genotype-3 in chronic hepatitis c | [Journal of College of Physicians and Surgeons--Pakistan : JCPSP • 2014]

Author(s):

1. Muhammad Saleem Qureshi: Department of Medicine, Khan Research Laboratories (KRL) Hospital, Islamabad-44000, Pakistan

2. Musarrat Iqbal: Department of Medicine, Khan Research Laboratories (KRL) Hospital, Islamabad-44000, Pakistan

3. Ali Zohair Nomani: Department of Medicine, Khan Research Laboratories (KRL) Hospital, Islamabad-44000, Pakistan

4. Kamran Rasheed: Department of Medicine, Khan Research Laboratories (KRL) Hospital, Islamabad-44000, Pakistan

Abstract:

The aim of the present study was to determine the efficacy and side effect profile of conventional interferon alpha-2b plus ribavirin for treating chronic hepatitis C genotype-3 infections in Pakistan. The study was conducted on treating 220 treatment-naïve individuals at KRL Hospital with conventional interferon given for 6 months. Both the response and side effects were analyzed using simple descriptive statistics. Out of total cohort, 84.92% (169 out of 199) achieved end of treatment response (ETR) while 63.31% (126 out of 199) achieved sustained virological response (SVR). Leukopenia, gastrointestinal and miscellaneous systemic complaints were the most common adverse effects. In the context of a low ETR and SVR but a similar side effect profile as that of pegylated regimes, conventional therapy needs to be replaced with peg-interferon as the treatment of choice.

Page(s): 70-72

DOI: DOI not available

Published: Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 24, Issue: 1, Year: 2014

Keywords:

Hepatitis C virus , conventional , Sustained virological response , Interferon , Side effects , Genotype 3 , End of treatment response

References:

References are not available for this document.

Citations

Citations are not available for this document.

Citations

Downloads

Views